Neil Sengupta to Cost-Benefit Analysis
This is a "connection" page, showing publications Neil Sengupta has written about Cost-Benefit Analysis.
Connection Strength
0.608
-
Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score. PLoS One. 2016; 11(2):e0147237.
Score: 0.460
-
Extensive testing or focused testing of patients with elevated liver enzymes. J Hepatol. 2017 02; 66(2):313-319.
Score: 0.120
-
Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. Am J Gastroenterol. 2015 Sep; 110(9):1298-304.
Score: 0.028